These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36040662)

  • 21. Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity.
    Bae S; Ko JH; Choi JY; Park WJ; Lim SY; Ahn JY; Song KH; Lee KH; Song YG; Chan Kim Y; Park YS; Choi WS; Jeong HW; Kim SW; Kwon KT; Kang ES; Kim AR; Jang S; Kim B; Kim SS; Jang HC; Choi JY; Kim SH; Peck KR
    Clin Microbiol Infect; 2022 Oct; 28(10):1390.e1-1390.e7. PubMed ID: 35598855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
    Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
    BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.
    Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P
    Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain.
    Fernández-Ciriza L; González Á; Del Pozo JL; Fernández-Montero A; Carmona-Torre F; Carlos S; Sarasa MDM; Reina G
    Sci Rep; 2022 Oct; 12(1):15606. PubMed ID: 36207324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
    Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
    BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
    Andrews N; Tessier E; Stowe J; Gower C; Kirsebom F; Simmons R; Gallagher E; Thelwall S; Groves N; Dabrera G; Myers R; Campbell CNJ; Amirthalingam G; Edmunds M; Zambon M; Brown K; Hopkins S; Chand M; Ladhani SN; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Jan; 386(4):340-350. PubMed ID: 35021002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
    Wei J; Pouwels KB; Stoesser N; Matthews PC; Diamond I; Studley R; Rourke E; Cook D; Bell JI; Newton JN; Farrar J; Howarth A; Marsden BD; Hoosdally S; Jones EY; Stuart DI; Crook DW; Peto TEA; Walker AS; Eyre DW;
    Nat Med; 2022 May; 28(5):1072-1082. PubMed ID: 35165453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
    Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
    Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
    Kerr S; Joy M; Torabi F; Bedston S; Akbari A; Agrawal U; Beggs J; Bradley D; Chuter A; Docherty AB; Ford D; Hobbs R; Katikireddi SV; Lowthian E; de Lusignan S; Lyons R; Marple J; McCowan C; McGagh D; McMenamin J; Moore E; Murray JK; Owen RK; Pan J; Ritchie L; Shah SA; Shi T; Stock S; Tsang RSM; Vasileiou E; Woolhouse M; Simpson CR; Robertson C; Sheikh A
    PLoS Med; 2022 Feb; 19(2):e1003927. PubMed ID: 35192598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Outcome of BNT162b2, ChAdOx1-Sand mRNA-1273 Vaccines and Two Boosters: A Prospective Longitudinal Real-World Study.
    Kamal SM; Naghib MM; Daadour M; Alsuliman MN; Alanazi ZG; Basalem AA; Alaskar AM; Saed K
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period.
    Kim JY; Lim SY; Park S; Kwon JS; Bae S; Park JY; Cha HH; Seo MH; Lee HJ; Lee N; Kim K; Shum D; Jee Y; Kim SH
    J Infect Dis; 2022 Mar; 225(5):777-784. PubMed ID: 34850034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
    Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S
    Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2.
    Hermosilla E; Coma E; Xie J; Feng S; Cabezas C; Méndez-Boo L; Fina F; Ballo E; Martínez M; Medina-Peralta M; Argimon JM; Prieto-Alhambra D
    Nat Commun; 2022 Mar; 13(1):1639. PubMed ID: 35322045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
    Vogel E; Kocher K; Priller A; Cheng CC; Steininger P; Liao BH; Körber N; Willmann A; Irrgang P; Held J; Moosmann C; Schmidt V; Beileke S; Wytopil M; Heringer S; Bauer T; Brockhoff R; Jeske S; Mijocevic H; Christa C; Salmanton-García J; Tinnefeld K; Bogdan C; Yazici S; Knolle P; Cornely OA; Überla K; Protzer U; Schober K; Tenbusch M
    EBioMedicine; 2022 Nov; 85():104294. PubMed ID: 36206622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
    Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
    J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19.
    Cha HH; Lim SY; Kwon JS; Kim JY; Bae S; Jung J; Kim SH
    Korean J Intern Med; 2022 Mar; 37(2):455-459. PubMed ID: 35272444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.